Clinical Research Site

Los Angeles, California 90095-7065

1 studies enrolling now · 15 studies all time

What they study most

Agitation in Patients With Dementia of the Alzheimer's Type, Agitation,Psychomotor, Alzheimer Disease, Essential Hypertension, Hidradenitis Suppurativa, Major Depressive Disorder, Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms, Migraine, Psoriatic Arthritis, Pulmonary Aspergillosis, Refractory IPA, Scabies

Studies at this site

• Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol — Recruiting now
• Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study) — Stopped early
• An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study) — Completed
• Initiating Early Control of Migraine Pain and Associated Symptoms — Completed
• Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol — Completed
• Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE) — Completed
• Hidradenitis Suppurativa Study of Izokibep — Stopped early
• Hidradenitis Suppurativa Phase 2b Study of Izokibep — Completed
• Psoriatic Arthritis Study of Izokibep — Stopped early
• Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis — Stopped early
• Assessing Clinical Outcomes in Alzheimer's Disease Agitation — Completed
• Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT) — Completed
• Maximizing Outcomes in Treating Acute Migraine — Completed
• A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies — Completed
• An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension — Completed